We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of TZDs in treatment of diabetes mellitus patients with renal impairment. We searched PubMed, EMBASE and Cochrane Central Register of Controlled Trials. Randomized controlled trials (RCTs), cohort studies, and case-control studies that investigated the effects of TZDs in patients with diabetes and renal impairment were eligible. Outcomes included glycosylated hemoglobin, fasting plasma glucose, serum lipids, and patient-important outcomes (i.e. hypoglycemia, weight, edema, cardiovascular events and mortality). 19 RCTs and 3 cohort studies involving 21,803 patients with diabetes and renal impairment were included. Meta-analysis of RCTs showed that TZDs could significantly reduce HbA1c (MD −0.64,  95%CI −0.93 to −0.35), FPG (MD −26.27, 95%CI −44.90 to −7.64) and increase HDL levels (MD 3.70,  95%CI 1.10, 6.29) . TZDs could increase weight (MD 3.23, 95% CI 2.29 to 4.16) and risk of edema (RR 2.96, 95% CI 1.22 to 7.20). Their effects on risk of hypoglycemia (RR 1.46, 95% CI 0.65 to 3.29), heart failure (RR 0.64, 95% CI 0.15 to 2.66), angina (RR 1.45, 95% CI 0.23 to 8.95) and all-cause mortality (RR 0.40, 95% CI 0.08 to 2.01) are uncertain. Results from cohort studies were similar to RCTs.
glycaemia in Diabetes (RECORD) study, however, did not rule out an elevated risk of myocardial infarction amongst participants treated with rosiglitazone 11 . The Veterans Affairs Diabetes Trial (VADT) even found that use of rosiglitazone was associated with decreased risk of cardiovascular composite outcome and cardiovascular death 12 . Recently FDA repealed restriction of rosiglitazone. Though accumulating studies focused on cardiovascular safety of TZDs treatment, most of these studies excluded patients with obvious renal impairment. The safety of TZDs in treatment of diabetes patients with renal impairment has still been uncertain. Considering high prevalence of cardiovascular events in patients with renal impairment, whether TZDs increase the risk of heart failure, myocardial infraction and mortality has been a major concern of clinician.
Most of reported studies of TZDs treating in diabetes patient with renal impairment were small sample sizes (especially in randomized control trials) and had conflicting findings on cardiovascular outcomes [13] [14] [15] [16] [17] . A cohort study found that TZDs use was associated with better survival in hemodialysis patients with type 2 diabetes 14 , but another cohort study found that diabetes patients prescribed rosiglitazone had significantly higher all-cause mortality and cardiovascular mortality 15 . Except for mortality, whether treatment of TZDs in diabetes patients with renal impairment increase the risk of heart failure was inconsistent 16, 17 . Though guideline approved treatment of TZDs in patients with chronic renal failure 2, 18 , but these recommends mainly based on pharmacokinetics not clinical researches.
Consequently, we conducted this systematic review and meta-analysis to investigate the efficacy and safety of TZDs in treatment of patients with diabetes mellitus and renal impairment.
Results
We identified a total 1,936 potentially relevant reports in the initial retrieval. Finally, 22 studies were included in data analysis, including 19 RCTs (n = 1,818) and 3 cohort studies (n = 19,985) ( Fig. 1 ). Table 1 summarized the characteristics of the 22 included studies. The 19 RCTs involved a total of 1,818 participants, with mean age ranging from 43.4 to 71.1 years, mean baseline HbA1c 6.9 to 9.2%, mean fasting plasma glucose 135.7 to 205.2 mg/dl, and mean duration of diabetes 5.5 to 17.5 years. Of the 19 RCTs, one (5.3%) enrolled patients undergo renal transplantation, five (26.3%) enrolled dialysis patients, and thirteen (68.4%) trials included patients with mild to moderate renal impairment. Fourteen (73.7%) trials used pioglitazone as intervention, four (21.1%) used rosiglitazone, one (5.3%) used both pioglitazone and rosiglitazone.
Study characteristics.
Of the three cohort studies, one was prospective and two were retrospective studies. These cohort studies included a total of 19,985 participants; mean age ranged from 63.5 to 66.1 years and mean follow-up 24 week to 270 days. All these cohort studies enrolled ESRD patients.
Risk of bias assessment.
All the 19 RCTs were at moderate to high risk of bias 16, 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (Supplementary   Table 1 ). Of the three cohort studies, one 15 was at low risk of bias, one moderate risk 14 and another 36 high risk.
( Supplementary Table 2 ). Publication bias assessment. Publication bias was investigated using the funnel plot and Egger's tests.
No evidence of publication bias was found for the outcomes of FPG, HbA1c, TC, TG, and HDL. Owing to the limited numbers of the included studies or low events rate, publication bias investigation was not performed for other outcomes.
Efficacy of TZDs.
HbA1c. Fifteen RCTs reported change of HbA1c from baseline. Compared with all controls, HbA1c in TZDs group significantly decreased, with substantial statistical heterogeneity (MD −0.64, 95% CI −0.93 to −0.35, I 2 = 69%) ( Fig. 2 ). Subgroup analysis showed that, compared with placebo or no additional drugs, levels of HbA1c in TZDs groups were significantly lower (MD −0.90, 95% CI −1.24 to −0.56, I 2 = 73%), while no significance between groups was observed when compared with active drugs (MD −0.16, 95% CI −0.50 to 0.18, I 2 = 0%; test for subgroup differences: P = 0.003) ( Supplementary Table 3 ).
Fasting plasma glucose. Changes in FPG from baseline were reported in 10 RCTs. Compared with controls, treatment of TZDs was associated with a significant decrease in FPG levels, with considerable statistical heterogeneity (MD −26.27, 95% CI −44.90 to −7.64, I 2 = 89%) ( Fig. 3 ). Subgroup analysis showed that, when compared with placebo or no additional drugs, TZDs significantly decreased FPG levels (MD −32.26, 95% CI −53.13 to −11.39, I 2 = 90%); comparison with active drugs as controls illustrated a lack of significant effect (MD 3.94, 95%CI −12.96 to 20.84, I 2 = 0%; test for subgroup differences: P = 0.008) (Supplementary Table 3 ).
Serum lipids and lipoproteins.
A total of 11 trials reported changes in triacylglycerol (TG). Compared with controls, TG in TZDs group had no significant decrease (MD −17.18, 95% CI −37.25 to 2.90, I 2 = 61%) ( Fig. 4A ). Subgroup analysis showed that, compared with controls, levels of TG in pioglitazone group were significantly lower (MD −26.38, 95% CI −40.56 to −12.19, I 2 = 25%); no significance was observed between rosiglitazone group and controls. (MD 31.81, 95% CI −24.73 to 88.35, I 2 = 61%; test for subgroup differences: P = 0.05) (Supplementary Table 3 ).
Twelve trials reported changes in total cholesterol (TC), no significant differences between groups were observed in the analysis of TC (MD −0.02, 95% CI −8.04 to 8.00, I 2 = 31%) ( Fig. 4B ). Subgroup analysis showed that, compared with controls, treatment of pioglitazone significantly decreased TC levels (MD −7.00, 95% CI −13.77 to −0.23, I 2 = 0%), but treatment rosiglitazone significantly increased TC levels (MD 13.51, 95% CI 0.48 to 26.54, I 2 = 0%; test for subgroup differences: P = 0.006) (Supplementary Table 3 ).
Five trials reported changes in low-density lipoprotein (LDL). There were no significant changes in LDL levels between TZDs group and controls (MD 4.49, 95% CI −6.44 to 15.43, I 2 = 53%) ( Fig. 4C ). Subgroup analysis showed that, compared with controls, LDL levels had no significant decrease both in pioglitazone group (MD 8.30, 95% CI −12.82 to 29.41, I 2 = 73%) and rosiglitazone group (MD 4.66, 95% CI −6.61 to 15.94, I 2 = 0%; test for subgroup differences: P = 0.77) (Supplementary Table 3 ).
Ten trials reported changes in high-density lipoprotein (HDL). HDL in TZDs group was significant increase, and the heterogeneity was moderate (MD 3.70, 95% CI 1.10 to 6.29, I 2 = 42%) ( Fig. 4D ). Subgroup analysis by type of TZDs showed that treatment of pioglitazone (MD 4.84, 95% CI 2.50 to 7.18, I 2 = 22%), but not rosiglitazone (MD −1.92, 95% CI −6.66 to 2.82, I 2 = 0%; test for subgroup differences: P = 0.01), significantly elevated HDL levels (Supplementary Table 3 ).
Safety of TZDs.
Hypoglycemia. Six trials involving 1,178 participants reported hypoglycemia, of which two trials 17, 23 compared TZDs versus active drugs (sufonylureas, DPP-4), and four trials 16, 21, 25, 27 compared TZDs versus placebo/no additional drugs. One trial 23 used both rosiglitazone and pioglitazone as intervention, four trials 16, 17, 25, 27 used pioglitazone and one trial 21 used rosiglitazone as intervention. Meta-analysis suggested that, compared with controls, there was no significant differences between groups in the risk of hypoglycemia and the heterogeneity was low (RR 1.46, 95% CI 0.65 to 3.29, I 2 = 0%) ( Supplementary Fig. 1 ).
One cohort study 36 involving 12,350 participants reported hypoglycemia. There was no significant difference in the risk of hypoglycemia between TZDs and control (RR 0.99, 95% CI 0.65 to 1.52).
Weight change. Five trials (n = 241) reported changes in weight, of which four trials enrolled patients with ESRD and treated patients with pioglitazone. All trials used placebo/no additional drugs as controls. Compared with control group, treatment of TZDs significantly increased body weight (MD 3.23, 95% CI 2.29 to 4.16, I 2 = 0%) ( Fig. 5 ). Of these five trails, two trials reported changes in dry weight. Considering there may be some differences between dry weight and total weight, we also did meta-analysis respectively. The results showed that total weight (MD 2.82, 95% CI 1.17 to 4.47, I 2 = 38%), but not dry weight (MD 0.95, 95% CI −11.57 to 13.46, I 2 = 0%) significantly increased in TZDs group. No cohort study reported weight changes.
Edema. Seven trials reported edema or worsening edema, of which three trials 17, 23, 28 compared TZDs versus active drugs, five trials 17, 21, 23, 24, 28 enrolled patients with non-ESRD, and the other two trials 16, 20 included patients with ESRD. One trial 23 compared TZDs (both rosiglitazone and pioglitazone) versus control, four trials 16, 17, 20, 28 compared pioglitazone versus control and the other two trials 21, 24 compared rosiglitazone versus control. Meta-analysis of seven RCTs showed that the risk of edema significantly increased in TZDs group compared with control (RR 2.96, 95% CI 1.22 to 7.20, I 2 = 0%) ( Fig. 6 ). We also did subgroup analyses by type of renal impairment, type of TZDs and type of control, but the subgroup differences had no statistical significance (Supplementary Table 3 ). No cohort study reported edema. Cardiovascular events. Of the five trials (n = 233) reporting heart failure, one 17 compared TZD versus active drugs (sulfonylureas), and the remaining four 16, 26, 27, 33 compared TZDs versus placebo/no additional drugs. One trial 33 used rosiglitazone as intervention and the other three trials used pioglitazone as intervention. Meta-analysis showed that TZDs-treatment did not increase the risk of heart failure (RR 0.64, 95% CI 0.15 to 2.66, I 2 = 0%) ( Table 2) . Three trials reported three angina events occurring in 168 patients. All these trials used pioglitazone as intervention. The pooling of those trials showed no statistically significant difference in the risk of angina between pioglitazone treatment and control (RR 1.45, 95% CI 0.23 to 8.95; I 2 = 0%) ( Table 2) . Two trials 16, 33 reported myocardial infarction, but no event occurred in each group. No study reported the data of stroke.
One trial 34 (RR 0.33, 95% CI 0.01 to 7.82) and one cohort study 15 (RR 1.23, 95% CI 0.87 to 1.75) reported cardiovascular mortality, both results showed that TZDs treatment may not increase the risk of cardiovascular mortality ( Table 2) .
All-Cause Mortality. Five trials involving 878 participants reported all-cause mortality, of which three trials 17, 23, 28 compared TZDs versus active drugs (sufonylureas, DPP-4, metformin), two trials 33, 34 compared TZDs versus placebo/no additional drugs. Meta-analysis showed that TZDs were not associated with increased risk of all-cause mortality (RR 0.40, 95% CI 0.08 to 2.01; I 2 = 0%) ( Table 2) .
Meta-analysis of two cohort studies (n = 3,133) also showed that compared with control, TZDs did not increase the risk of all-cause mortality (RR 0.78, 95% CI 0.38 to 1.59; I 2 = 85%) ( Table 2) .
We did sensitivity analyses using pooling methods and statistical models regarding heterogeneity, and the results (hypoglycemia, weight, risk of edema, HF, angina and all-cause mortality) were similar.
Discussion
In this study, we found that TZDs may achieve improved glucose control relative to placebo in patients with diabetes and impaired renal functions. We did not observe difference in the glucose control effects between TZDs and other anti-diabetes medications. However, the effects of the two individual agents of TZDs on serum lipids may differ -subgroup analyses suggested that pioglitazone could elevate HDL and reduce TG and TC, but not with rosiglitazone. Our study also found that TZDs did not increase the risk of hypoglycemia. Compared with Several previous studies supported our findings. A meta-analysis 37 found that metformin, TZDs and sulfonylureas had similar hypoglycemic effect, which explained our findings that the changes of HbA1c and FPG had no statistical significance when compared with active drugs. The PROspective pioglitazone Clinical Trial in Macrovascular Events (PROactive) found that compared with placebo, pioglitazone reduced HbA1c, TG levels and increased HDL levels 38 . A meta-analysis including 23 RCTs, which compared pioglitazone or rosiglitazone against placebo in patients with type 2 diabetes, found that pioglitazone elevated HDL levels and reduced TG levels, but rosiglitazone increased LDL and TC levels 39 . Although TZDs exerted effects in reducing glucose, our meta-analysis indicated that TZDs played no role in the risk of hypoglycemia. Possible explanation behind this mechanism is the fact that TZDs are mainly metabolized by the liver. Indeed, current clinical practice guidelines recommendations state that TZDs can be used in patients with renal failure as TZDs do not increase the risk of hypoglycemia 2, 18 .
Although the adverse effects of weight gain and edema in TZDs-treated patients were established 11, [39] [40] [41] , the effects of TZDs on cardiovascular events and mortality remain to be further explored. On one hand, our findings were consistent with a few published meta-analyses that found treatment with TZDs did not increase the risk of MI 42, 43 , cardiovascular mortality, or all-cause mortality 44, 45 . The PROactive trial even showed that treatment with pioglitazone significantly reduced the risk of all-cause mortality, non-fatal MI and stroke 38 . These benefits may also exist in patients without diabetes 46 . The mechanism for the observed phenomenon is unclear. Since endothelial dysfunction is a strong predictor for future cardiovascular events in patients with coronary artery disease 47, 48 , one possible explanation is that TZDs may have benefit on endothelial function. TZDs, PPAR γ agonists, could exhibit anti-inflammatory properties 49, 50 and increase NO release from endothlial cells 51 , which may produce vasodilatation and attenuate vascular damage. Moreover, pioglitazone treatment could increase the number and function of endothelial progenitor cells (EPCs). Increased levels of EPCs, which enhance angiogenesis, promote vascular repair, and improve endothelial function 52 , could reduce the risk of cardiovascular mortality in patients with coronary artery disease 48 . In patients with type 2 diabetes, pioglitazone showed an effect on ameliorating endothelial dysfunction, which was independent of its metabolic action 53, 54 . Indeed, a randomized, placebo-controlled, double-blind trial found that, after six months treatment, pioglitazone group had a significantly better coronary endothelial function compare to control 55 , further supporting the hypothesis.
However, a couple of other meta-analyses suggested that treatment with TZDs might increase risk of MI 8, 45 . The reasons of these seemingly conflicts may be due to the inclusion of different TZDs in those studies. Previous studies showed that pioglitazone may reduce ischemic disease and all-cause mortality in patients with type 2 diabetes 38 , while rosiglitazone may increase cardiovascular events especially MI 8, 9, 56 . The underlying mechanisms for the apparent differences in cardiovascular risk and mortality have not been clearly understood, but one possible explanation is that the two class of TZDs may have different effect on lipids, as mentioned above. And lipid abnormalities may cause endothelial cell toxicity and subsequently induce endothelial dysfunction. Moreover, pioglitazone has shown some potential benefit in preventing progression of atherosclerosis 57 , but rosiglitazone failed to show any potential benefit in this regard 58 .
Our study has several strengths. Firstly, to the best of our knowledge, this is the first systematic review and meta-analysis on the topic of efficacy and safety of TZDs treatment in patients with different degree of renal impairment. A published meta-analysis illustrated that TZDs significantly decreased urinary albumin and protein excretion in patients with diabetes, but they enrolled patients with normoalbuminuria or proteinuria 6 . Secondly, we systematically identified and included both randomized and non-randomized studies. Compared to previous reviews, we assessed both efficacy and safety outcomes of TZD-treated patients using quantitative methods. However, our findings should be interpreted cautiously due to some limitations. First of all, the risk of bias of most eligible studies were moderate to high. Secondly, due to limited number of the included studies, some subgroup analyses were not carried out. We could not analysis whether different type of TZDs have different effects on hypoglycemia, CV events and mortality. Thirdly, lack of universal standard to definite outcomes may add heterogeneity to this analyses.
In summary, this meta-analysis suggests TZDs treatment in diabetes patients with renal impairment may improve glucose control and serum lipid, but may increase the risk of weight gain and edema. However, the effects of TZDs on cardiovascular events and all-cause mortality were uncertain, mainly because of the limited sample sizes and inadequate power. More carefully designed, conducted, adequately powered studies (both RCTs and observational studies) are warranted to examine the effect on the long-term patient important outcomes. Table 2 . Risk of cardiovascular events and mortality in patients with diabetes mellitus and renal impairment for the TZDs versus control groups.
Methods
We followed the standards set by Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 59 Text 1) . We also screened ClinicalTrials.gov and reference lists of published reviews to identify additional relevant studies. Only studies published in English were included.
Study screening and data collection. Two authors (WW and XZ) independently screened titles/abstracts
and full-text articles to identify eligibility, assessed risk of bias, and collected data from each eligible study. We used standardized, pilot-tested forms, together with detailed instructions. For the included studies, we extracted data regarding study characteristics (study design, total number of patients, length of follow up and number of patients lost to follow up), baseline characteristics (gender, age, duration of diabetes, type of renal impairment, FPG, HbA1c), intervention and outcomes of interest. Disagreement was resolved through discussion or, if required, adjudication by a third author (JSWK).
Risk of bias assessment. We assessed risk of bias of RCTs using a modified version of the Cochrane
Collaboration's tool for assessing risk of bias 61, 62 . The items included random sequence generation, allocation concealment, blinding of participants, caregivers, and assessors of outcomes, selective reporting, adequate follow up, and comparability. We used the modified Newcastle-Ottawa Scale (NOS) for assessing the quality of cohort studies. We removed "representativeness of the exposed cohort" and "was follow-up long enough for outcomes to occur" as these items relate to applicability of results, and added "assessment of prognostic factors" and "similar co-interventions" to assess comparability between groups 63, 64 .
Data synthesis and analysis. We analyzed RCTs and observational studies separately using risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes with corresponding 95% confidence intervals (CIs) to compare difference between TZDs and control groups. We pooled RRs using the Mantel-Haenszel method, and MD using the inverse variance method. Statistical heterogeneity among studies was examined by the Chi-square test and quantified by the I 2 statistic 65 . We explored sources of heterogeneity using the following subgroup analyses: type of renal impairment (non-ESRD vs. ESRD); type of TZDs (pioglitazone vs. rosiglitazone) and type of control (placebo/no additional drugs vs. active treatment). We carried out sensitivity analyses by using alternative pooling methods (Peto vs. Mantel-Haenszel method), and statistical models regarding heterogeneity (random-effects vs. fixed-effect). We also detected publication bias by visually examining symmetry of funnel plots and Egger's tests.
